Systemic therapy for locally advanced and metastatic non-small cell lung cancer: A review
Carcinoma, Non-Small-Cell Lung
Protein Kinase Inhibitors
Receptor Protein-Tyrosine Kinases
Improved understanding of the biology and molecular subtypes of non-small cell lung cancer have led to more biomarker-directed therapies for patients with metastatic disease. These biomarker-directed therapies and newer empirical treatment regimens have improved overall survival for patients with metastatic non-small cell lung cancer.